Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics.

Ankrom W, Yee KL, Sanchez RI, Adedoyin A, Fan L, Marbury T, Preston RA, Iwamoto M, Khalilieh SG.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00326-18. doi: 10.1128/AAC.00326-18. Print 2018 Aug.

PMID:
29891610
2.

Multiple Doses of Rifabutin Reduce Exposure of Doravirine in Healthy Subjects.

Khalilieh SG, Yee KL, Sanchez RI, Liu R, Fan L, Martell M, Jordan H, Iwamoto M.

J Clin Pharmacol. 2018 May 3. doi: 10.1002/jcph.1103. [Epub ahead of print]

PMID:
29723418
3.

Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men.

Yee KL, McCrea J, Panebianco D, Liu W, Lewis N, Cabalu T, Ramael S, Wrishko RE.

Clin Drug Investig. 2018 Jul;38(7):631-638. doi: 10.1007/s40261-018-0650-4.

PMID:
29705869
4.

Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans.

Sanchez RI, Fillgrove KL, Yee KL, Liang Y, Lu B, Tatavarti A, Liu R, Anderson MS, Behm MO, Fan L, Li Y, Butterton JR, Iwamoto M, Khalilieh SG.

Xenobiotica. 2018 Mar 28:1-11. doi: 10.1080/00498254.2018.1451667. [Epub ahead of print]

PMID:
29557716
5.

Furfural and 5-hydroxymethyl-furfural degradation using recombinant manganese peroxidase.

Yee KL, Jansen LE, Lajoie CA, Penner MH, Morse L, Kelly CJ.

Enzyme Microb Technol. 2018 Jan;108:59-65. doi: 10.1016/j.enzmictec.2017.08.009. Epub 2017 Aug 31.

PMID:
29108628
6.

Evaluation of Model-Based Prediction of Pharmacokinetics in the Renal Impairment Population.

Yee KL, Li M, Cabalu T, Sahasrabudhe V, Lin J, Zhao P, Jadhav P.

J Clin Pharmacol. 2017 Oct 27. doi: 10.1002/jcph.1022. [Epub ahead of print]

PMID:
29077203
7.

A Randomized Trial to Assess the Effect of Doravirine on the QTc Interval Using a Single Supratherapeutic Dose in Healthy Adult Volunteers.

Khalilieh SG, Yee KL, Fan L, Liu R, Heber W, Dunzo E, Triantafyllou I, Hussaini A, Iwamoto M.

Clin Drug Investig. 2017 Oct;37(10):975-984. doi: 10.1007/s40261-017-0552-x.

PMID:
28785879
8.

Tumor necrosis factor ╬▒ Inhibition for Alzheimer's Disease.

Chang R, Yee KL, Sumbria RK.

J Cent Nerv Syst Dis. 2017 May 15;9:1179573517709278. doi: 10.1177/1179573517709278. eCollection 2017. Review.

9.

The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.

Yee KL, Khalilieh SG, Sanchez RI, Liu R, Anderson MS, Manthos H, Judge T, Brejda J, Butterton JR.

Clin Drug Investig. 2017 Jul;37(7):659-667. doi: 10.1007/s40261-017-0513-4.

PMID:
28353169
10.

The Effect of Food on Doravirine Bioavailability: Results from Two Pharmacokinetic Studies in Healthy Subjects.

Behm MO, Yee KL, Liu R, Levine V, Panebianco D, Fackler P.

Clin Drug Investig. 2017 Jun;37(6):571-579. doi: 10.1007/s40261-017-0512-5.

PMID:
28349328
11.

Effect of gender and age on the relative bioavailability of doravirine: results of a Phase I trial in healthy subjects.

Behm MO, Yee KL, Fan L, Fackler P.

Antivir Ther. 2017;22(4):337-344. doi: 10.3851/IMP3142. Epub 2017 Feb 16.

PMID:
28206979
12.

Erratum to: A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir.

Anderson MS, Khalilieh S, Yee KL, Liu R, Fan L, Rizk ML, Shah V, Hussaini A, Song I, Ross LL, Butterton JR.

Clin Pharmacokinet. 2017 Jun;56(6):679-681. doi: 10.1007/s40262-017-0517-5. No abstract available.

PMID:
28185217
13.

Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics.

Khalilieh S, Yee KL, Liu R, Fan L, Sanchez RI, Auger P, Triantafyllou I, Stypinski D, Lasseter KC, Marbury T, Iwamoto M.

J Clin Pharmacol. 2017 Jun;57(6):777-783. doi: 10.1002/jcph.857. Epub 2016 Dec 27.

PMID:
28026013
14.

Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study.

Khalilieh S, Yee KL, Sanchez RI, Triantafyllou I, Fan L, Maklad N, Jordan H, Martell M, Iwamoto M.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01364-16. doi: 10.1128/AAC.01364-16. Print 2017 Feb.

15.

Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects.

Yee KL, Sanchez RI, Auger P, Liu R, Fan L, Triantafyllou I, Lai MT, Di Spirito M, Iwamoto M, Khalilieh SG.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01757-16. doi: 10.1128/AAC.01757-16. Print 2017 Feb.

16.

Transgenic switchgrass (Panicum virgatum L.) targeted for reduced recalcitrance to bioconversion: a 2-year comparative analysis of field-grown lines modified for target gene or genetic element expression.

Dumitrache A, Natzke J, Rodriguez M Jr, Yee KL, Thompson OA, Poovaiah CR, Shen H, Mazarei M, Baxter HL, Fu C, Wang ZY, Biswal AK, Li G, Srivastava AC, Tang Y, Stewart CN Jr, Dixon RA, Nelson RS, Mohnen D, Mielenz J, Brown SD, Davison BH.

Plant Biotechnol J. 2017 Jun;15(6):688-697. doi: 10.1111/pbi.12666. Epub 2017 Feb 20.

17.

A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir.

Anderson MS, Khalilieh S, Yee KL, Liu R, Fan L, Rizk ML, Shah V, Hussaini A, Song I, Ross LL, Butterton JR.

Clin Pharmacokinet. 2017 Jun;56(6):661-669. doi: 10.1007/s40262-016-0458-4. Erratum in: Clin Pharmacokinet. 2017 Jun;56(6):679-681.

PMID:
27699622
18.

Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man.

Gotter AL, Forman MS, Harrell CM, Stevens J, Svetnik V, Yee KL, Li X, Roecker AJ, Fox SV, Tannenbaum PL, Garson SL, Lepeleire ID, Calder N, Rosen L, Struyk A, Coleman PJ, Herring WJ, Renger JJ, Winrow CJ.

Sci Rep. 2016 Jun 3;6:27147. doi: 10.1038/srep27147.

19.

In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans.

Cui D, Cabalu T, Yee KL, Small J, Li X, Liu B, Maciolek C, Smith S, Liu W, McCrea JB, Prueksaritanont T.

Xenobiotica. 2016 Oct;46(10):882-95. doi: 10.3109/00498254.2015.1129565. Epub 2016 Feb 10.

PMID:
26864332
20.

Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects.

Sun H, Yee KL, Gill S, Liu W, Li X, Panebianco D, Mangin E, Morrison D, McCrea J, Wagner JA, Troyer MD.

J Psychopharmacol. 2015 Nov;29(11):1159-69. doi: 10.1177/0269881115609015. Epub 2015 Oct 13. Erratum in: J Psychopharmacol. 2016 Jan;30(1):95.

PMID:
26464455
21.

A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals.

Sch├╝rmann D, Sobotha C, Gilmartin J, Robberechts M, De Lepeleire I, Yee KL, Guo Y, Liu R, Wagner F, Wagner JA, Butterton JR, Anderson MS.

AIDS. 2016 Jan 2;30(1):57-63. doi: 10.1097/QAD.0000000000000876.

PMID:
26372481
22.

Development of In Vitro-In Vivo Correlation for Amorphous Solid Dispersion Immediate-Release Suvorexant Tablets and Application to Clinically Relevant Dissolution Specifications and In-Process Controls.

Kesisoglou F, Hermans A, Neu C, Yee KL, Palcza J, Miller J.

J Pharm Sci. 2015 Sep;104(9):2913-22. doi: 10.1002/jps.24362. Epub 2015 Jan 21.

PMID:
25611455
23.

Consolidated bioprocessing of transgenic switchgrass by an engineered and evolved Clostridium thermocellum strain.

Yee KL, Rodriguez M Jr, Thompson OA, Fu C, Wang ZY, Davison BH, Mielenz JR.

Biotechnol Biofuels. 2014 May 22;7:75. doi: 10.1186/1754-6834-7-75. eCollection 2014.

24.

The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold.

Gotter AL, Winrow CJ, Brunner J, Garson SL, Fox SV, Binns J, Harrell CM, Cui D, Yee KL, Stiteler M, Stevens J, Savitz A, Tannenbaum PL, Tye SJ, McDonald T, Yao L, Kuduk SD, Uslaner J, Coleman PJ, Renger JJ.

BMC Neurosci. 2013 Aug 28;14:90. doi: 10.1186/1471-2202-14-90.

25.

Drug-drug interaction studies: regulatory guidance and an industry perspective.

Prueksaritanont T, Chu X, Gibson C, Cui D, Yee KL, Ballard J, Cabalu T, Hochman J.

AAPS J. 2013 Jul;15(3):629-45. doi: 10.1208/s12248-013-9470-x. Epub 2013 Mar 30. Review.

26.

Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.

Sun H, Kennedy WP, Wilbraham D, Lewis N, Calder N, Li X, Ma J, Yee KL, Ermlich S, Mangin E, Lines C, Rosen L, Chodakewitz J, Murphy GM.

Sleep. 2013 Feb 1;36(2):259-67. doi: 10.5665/sleep.2386.

27.

Evaluation of the bioconversion of genetically modified switchgrass using simultaneous saccharification and fermentation and a consolidated bioprocessing approach.

Yee KL, Rodriguez M Jr, Tschaplinski TJ, Engle NL, Martin MZ, Fu C, Wang ZY, Hamilton-Brehm SD, Mielenz JR.

Biotechnol Biofuels. 2012 Nov 12;5(1):81. doi: 10.1186/1754-6834-5-81.

28.

Integrin-mediated signalling through the MAP-kinase pathway.

Yee KL, Weaver VM, Hammer DA.

IET Syst Biol. 2008 Jan;2(1):8-15. doi: 10.1049/iet-syb:20060058. Review.

PMID:
18248081
29.

Adhesive dynamics simulation of neutrophil arrest with deterministic activation.

Krasik EF, Yee KL, Hammer DA.

Biophys J. 2006 Aug 15;91(4):1145-55. Epub 2006 May 26.

Supplemental Content

Support Center